High Cardiac Risk of E-cigarettes: Russian Expert

Industry Insight by 2FIRSTS.ai
Dec.06.2023
High Cardiac Risk of E-cigarettes: Russian Expert
E-cigarette use increases cardiovascular disease risk, raises the chance of heart attacks and strokes by 56% and 33% respectively, warns Russian expert.

According to recent news from A42.RU, Dr. Aleksey Alekseyevichkov, head of cardiology at Kuzbass, Russia, and a candidate for medical science, has stated that e-cigarettes are extremely harmful, including a significant increase in the risk of cardiovascular diseases.

 

He emphasized that e-cigarettes are more likely to cause heart disease and stroke compared to regular cigarettes, with users facing a 56% increased risk of heart attacks and a one-third increased risk of stroke.

 

According to Alekseyevko, e-cigarette use can lead to the loss of elasticity in blood vessel walls, affecting oxygen supply and making users more prone to symptoms such as irregular heartbeat, chest pain, and rapid heart rate. Additionally, toxic substances produced by e-cigarettes can increase the risk of blood clotting and arterial hardening, with higher risk observed among women.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

From Partnership to Acquisition: Why KT&G Is Betting on the Global Nicotine Pouch Market
From Partnership to Acquisition: Why KT&G Is Betting on the Global Nicotine Pouch Market
As global competition in the nicotine pouch market accelerates, Korea’s tobacco major KT&G has moved with a “Partnership + Acquisition” strategy, teaming up with Altria to acquire Nordic pouch maker Another Snus Factory (brand “LOOP”). Why deploy capital now, and why take this route? Drawing on company disclosures, regulatory monitoring and on-site observations from InterTabac Dortmund, 2Firsts analyzes KT&G’s strategic calculus and the signals behind this move.
Nov.05
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
Alan Zhao: What Altria’s on! PLUS Authorization Really Signals About FDA PMTA Enforcement
In this in-depth commentary for 2Firsts, Alan Zhao examines what Altria’s on! PLUS authorization really signals about FDA PMTA enforcement. Beyond the headline approval, FDA’s language, process design and product choices offer rare insight into how nicotine pouch regulation is taking shape—and what it means for industry compliance, in one of the earliest expert reads of the decision.
Regulations
Dec.20 by 2Firsts Perspectives
Altria CEO Billy Gifford to Retire; Sal Mancuso Named Successor
Altria CEO Billy Gifford to Retire; Sal Mancuso Named Successor
Altria Group, Inc. (NYSE: MO) announced that CEO Billy Gifford will retire at the conclusion of the 2026 Annual Meeting of Shareholders on May 14, 2026, after more than 30 years with the company. The Board of Directors has elected Salvatore (Sal) Mancuso, Altria’s current Executive Vice President and CFO, to succeed him as CEO.
Dec.12 by 2FIRSTS.ai
JT launches half-price Ploom AURA promotion across online and offline channels
JT launches half-price Ploom AURA promotion across online and offline channels
Japan Tobacco (JT) has announced a limited-time promotion on selected standard colors of its heated tobacco device Ploom AURA, running from 8 December 2025 to 18 January 2026. During the campaign, the starter kit price will be cut from 2,980 yen (approximately US$19.20) to 1,480 yen (around US$9.53).
Dec.05 by 2FIRSTS.ai
Russian Police Seize Over 150,000 Counterfeit E-Cigarettes Worth More Than USD 1.65 Million
Russian Police Seize Over 150,000 Counterfeit E-Cigarettes Worth More Than USD 1.65 Million
Russian police in Tambov have detained a man for storing and selling unmarked e-cigarettes. Over 150,000 counterfeit e-cigarettes, cartridges, and e-liquids were seized, valued at more than 126.5 million rubles (approximately USD 1.65 million). Tests revealed that the nicotine content of the seized products exceeded the levels stated on their packaging. A criminal case has been opened under Article 171.1, Part 6 of the Russian Criminal Code.
Dec.09 by 2FIRSTS.ai
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
Interpreting FDA’s on! PLUS Authorization: What the Agency’s Press Release Reveals About Its Nicotine Pouch Review Model
The U.S. Food and Drug Administration has confirmed that six on! PLUS nicotine pouch products have received Marketing Granted Orders (MGO) through the PMTA pathway. The authorizations were completed under the agency’s nicotine pouch review pilot program in “record time,” with the FDA citing lower levels of harmful constituents while stressing that the decision applies only to the specified products and does not mean they are safe or FDA approved.
Regulations
Dec.20